Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer.

Authors

null

Atsushi Takano

Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Atsushi Takano , Yoshihiro Yoshitake , Masanori Shinohara , Yataro Daigo

Organizations

Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, Department of Oral and Maxillofacial Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan, Department of clinical oncology, Shiga University of Medical Science, Otsu, Japan

Research Funding

Other Government Agency

Background: The improved understanding of cancer-specific oncoproteins could lead to the development of new biomarkers or therapeutic strategies for oral cancers. Methods: We conducted this study as follows: i) Identification of up-regulated genes in oral cancers by means of cDNA microarray, ii) Validation of clinicopathological significance of their protein expression by tissue microarray, iii) Examination of the growth on cancer cells by siRNA, iv) Elucidation of their biological effects on tumor growth. Results: We selected a secreted protein, OASEP1 (oral cancer-associated serum protein 1) as a candidate. Immunohistochemical staining showed that OASEP1 protein expression in cytoplasm was observed in 73 (74.4%) of 98 oral cancers that had undergone curative surgery. In addition, high level of OASEP1 expression was associated with poor prognosis for oral cancer patients (P = 0.0158, by log-rank test). Suppression of OASEP1 expression by siRNA for OASEP1 significantly suppressed the growth of oral cancer cell lines partly through apoptosis as detected by flow cytometric analysis, apoptosis assays, and time lapse imaging. In addition, siRNAs for a candidate receptor of OASEP1 also significantly inhibited its expression and the growth of oral cancer cells, indicating that the functional interaction between OASEP1 and its receptor could regulate the growth of oral cancer cells. Conclusions: Our data suggest that OASEP1 is a possible prognostic biomarker and therapeutic target for oral cancer.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Citation

J Clin Oncol 37, 2019 (suppl; abstr e14627)

DOI

10.1200/JCO.2019.37.15_suppl.e14627

Abstract #

e14627

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Annual Meeting

Characterization of URST1 as a biomarker and therapeutic target for oral cancer.

First Author: Atsushi Takano

Abstract

2022 ASCO Annual Meeting

A novel drug combination strategy that redesigns the pharmacological management of oral cancer.

First Author: Rajdeep Chakraborty

Abstract

2024 ASCO Annual Meeting

Impact on biomarker documentation in community oncology by optimizing clinical decision support.

First Author: Daniel Rubin

First Author: Julia R. Trosman